Telomeres and telomerase: targets for cancer chemotherapy?

Bibliography

• BLACKBURN EH: Structure and function of telomeres. Nature (1991) 350:569–573.
   PubMed Web of Science ®Google Scholar
• MEYNE J, RATLIFF RL, MOYZIS RK: Conservation of the human telomere sequence (TTAGGG). among verte-brates. Proc. Natl. Acad. ScL USA (1989) 86:7049–7053.
   PubMed Web of Science ®Google Scholar
• WRIGHT WE, TESMER VM, HUFFMAN KE, LEVENE SD, SHAY JW: Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. (1997) 11:2801–2809.
   PubMed Web of Science ®Google Scholar
• KRUK PA, RAMPINO NJ, BOHR VA: DNA damage and re-pair in telomeres: relation to ageing. Proc. Natl. Acad. ScL USA (1995) 92:258–262.
   PubMed Web of Science ®Google Scholar
• HARLEY CB, FUTCHER AB, GREIDER CW: Telomeresshorten during ageing of human fibroblasts. Nature (1990) 345:458–460.
   PubMed Web of Science ®Google Scholar
• ALLSOPP RC, HARLEY CB: Evidence for a critical telo-mere length in senescent human fibroblasts. Exp. Cell Res. (1995) 219:130–136.
   PubMed Web of Science ®Google Scholar
• FENG J, FUNK W, WANG S-S et al.: The RNA component of human telomerase. Science (1995) 269:1236–1241.
   PubMed Web of Science ®Google Scholar
• ••An extremely significant study describing the cloning of theRNA component of human telomerase. The authors detail the template region of hTR and show telomeric shortening followed by cell death after 23 to 26 doublings in HeLa cells transfected with antisense hTR. This study has enabled the rational design of antisense oligonucleotides targeted against hTR thus allowing a greater understanding of the role telomerase plays in cellular proliferation.
   Google Scholar
• NAKAMURA TM, MORIN GB, CHAPMAN KB et al.: Te- lomerase catalytic subunit homologs from fission yeast and human. Science (1997) 277:955–959.
   PubMed Web of Science ®Google Scholar
• •One of a number of independent studies identifying the hu-man telomerase catalytic subunit hTERT.
   Google Scholar
• MEYERSON M, COUNTER CM, EATON EN et al.: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortaliza-tion. Cell (1997) 90:785–795.
   PubMed Web of Science ®Google Scholar
• •One of a number of independent studies identifying the hu-man telomerase catalytic subunit hTERT.
   Google Scholar
• HARRINGTON L, ZHOU W, MCPHAIL T et al.: Human te- lomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. (1997) 11:3109–3115.
   PubMed Web of Science ®Google Scholar
• •One of a number of independent studies identifying the hu-man telomerase catalytic subunit hTERT.
   Google Scholar
• KILIAN A, BOWTELL DD, ABUD HE et al.: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. (1997) 6:2011–2019.
   PubMed Web of Science ®Google Scholar
• •One of a number of independent studies identifying the hu-man telomerase catalytic subunit hTERT.
   Google Scholar
• LINGNER J, HUGHES TR, SHEVCHENKO A, MANN M, LUNDBLAD V, CECH TR: Reverse transcriptase motifs in the catalytic subunit of telomerase. Science (1997) 276:561–567.
   PubMed Web of Science ®Google Scholar
• HARRINGTON L, MCPHAIL T, MAR V et al.: A mammaliantelomerase-associated protein. Science (1997) 275:973–977.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA J-I, SAITO M, NAKAMURA H, MATSUURA A, ISHIKAWA F: TLP1: A gene encoding a protein compo-nent of mammalian telomerase is a novel member of WD repeats family. Cell (1997) 88:875–884.
   PubMed Web of Science ®Google Scholar
• KIM NW, PIATYSZEK MA, PROWSE KR et al.: Specific as-sociation of human telomerase activity with immortal cells and cancer. Science (1994) 266:2011–2015.
   PubMed Web of Science ®Google Scholar
• ••This study details the TRAP assay, which has now become anear-ubiquitous standard method for the measurement of telomerase activity.
   Google Scholar
• SHAY JW, WERBIN H, WRIGHT WE: Telomeres and te-lomerase in human leukaemias. Leukemia (1996) 10:1255–1261.
   PubMed Web of Science ®Google Scholar
• HOLT SE, WRIGHT WE, SHAY JW: Regulation of te-lomerase activity in immortal cell lines. Md. Cell Biol. (1996) 16:2932–2939.
   Google Scholar
• COUNTER CM, HIRTE HW, BACCHETTI S, HARLEY CB: Te-lomerase activity in human ovarian carcinoma. Proc. Natl. Acad. ScL USA (1994) 91:2900–2904.
   PubMed Web of Science ®Google Scholar
• MORIN GB: Is telomerase a universal cancer target? J. Natl. Cancer Inst. (1995) 87:859–861.
   Google Scholar
• HAMILTON SE, COREY DR: Telomerase: anti-cancer tar-get or just a fascinating enzyme? Chem. Biol. (1996) 3:863–867.
   Google Scholar
• SHARMA S, RAYMOND E, SODA H et al.: Preclinical andclinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol. (1997) 8:1063–1074.
   PubMed Web of Science ®Google Scholar
• BLASCO MA, LEE H-W, HANDE MP et al.: Telomere short-ening and tumor formation by mouse cells lacking te-lomerase RNA. Cell (1997) 91:25–34.
   PubMed Web of Science ®Google Scholar
• LEE H-W, BLASCO MA, GOTTLIEB GJ, HORNER JW II,GREIDER CW, DEPINHO RA: Essential role of mouse telomerase in highly proliferative organs. Nature (1998) 392:569–574.
   PubMedGoogle Scholar
• •This study reveals the phenotype of mice lacking telomerase RNA indicating an essential role for telomerase in the long-term viability of high renewal organ systems.
   Google Scholar
• NIIDA H, MATSUMOTO T, SATOH H et al: Severe growthdefect in mouse cells lacking the telomerase RNA com-ponent. Nature Genet. (1998) 19:203–206.
   PubMed Web of Science ®Google Scholar
• BODNAR AG, OUELLETTE M, FROLKIS M et al.: Extensionof life-span by introduction of telomerase into normal human cells. Science (1998) 279:349–352.
   PubMed Web of Science ®Google Scholar
• MORIN GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesises TTAGGG repeats. Cell (1989) 59:521–529.
   PubMed Web of Science ®Google Scholar
• HOLT SE, NORTON JC, WRIGHT WE, SHAY JW: Compari-son of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit. Meth. Cell ScL (1996) 18:237–248.
   Google Scholar
• WRIGHT WE, SHAY JW, PIATYSZEK: Modifications of atelomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nu-cleic Acids Res. (1995) 23:3794–3795.
   PubMed Web of Science ®Google Scholar
• KIM NW, WU F: Advances in quantification and charac-terization of telomerase activity by the telomeric re-peat amplification protocol (TRAP). Nucleic Adds Res. (1997) 25:2595–2597.
   PubMed Web of Science ®Google Scholar
• TATEMATSU K, NAKAYAMA J, DANBARA M et al.: A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene (1996) 13:2265–2274.
   PubMed Web of Science ®Google Scholar
• OHYASHIKI K, OHYASHIKI JH, NISHIMAKI J et al.: Cyto-logical detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res. (1997) 57:2100–2103.
   PubMed Web of Science ®Google Scholar
• HEINE B, HUMMEL M, MULLER M, HEICAPPELL R, MILLER K, STEIN H: Non-radioactive measurement of te-lomerase activity in human bladder cancer, bladder washings, and in urine. J. Pathol. (1998) 184:71–76.
   PubMed Web of Science ®Google Scholar
• SUN D, CHEN S-F, VON HOFF D: A sensitive and rapid as-say method of human telomerase using dynabeads. Ann. Oncol. (1996) 7 (S1) :A240.
   Google Scholar
• SODER Al, HOARE SF, MUIR S, GOING JJ, PARKINSON EK, KEITH WN: Amplification, increased dosage and in situ expression of telomerase RNA gene in human cancer. Oncogene (1997) 14:1013–1021.
   PubMed Web of Science ®Google Scholar
• SODER Al, GOING JJ, KAYE SB, KEITH WN: Tumour spe-cific regulation of telomerase RNA gene expression visualised by in situ hybridisation. Oncogene (1998) 16:979–983.
   PubMed Web of Science ®Google Scholar
• LANSDORP PM, VERWOERD NP, VAN DE, RIJKE FM et al.:Heterogeneity in telomere length of human chromo-somes. Hum. Mol. Genet. (1996) 5:685–691.
   PubMed Web of Science ®Google Scholar
• HIYAMA E, GOLLAHON L, KATAOKA T et al.: Telomeraseactivity in human breast tumors. J. NatI Cancer Inst. (1996) 88:116–122.
   PubMed Web of Science ®Google Scholar
• CLARK GM, OSBORNE CK, LEVITT D, WU F, KIM NW: Te-lomerase activity and survival of patients with node-positive breast cancer. J. Natl. Cancer Inst. (1997) 89:1874–1881.
   PubMed Web of Science ®Google Scholar
• HIYAMA E, YOKOYAMA T, TATSUMOTO N et al: Te-lomerase activity in gastric cancer. Cancer Res. (1995) 55:3258–3262.
   PubMed Web of Science ®Google Scholar
• HIYAMA E, HIYAMA K, YOKOYAMA T, MATSUURA Y, PI-ATYSZEK MA, SHAY JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. (1995) 1:249–255.
   PubMed Web of Science ®Google Scholar
• BRESLOW RA, SHAY JW, GAZDAR AF, SRIVASTAVA S: Te-lomerase and early detection of cancer: a National Cancer Institute workshop. J. Natl. Cancer Inst. (1997) 89:618–623.
   PubMed Web of Science ®Google Scholar
• FARAONI I, TURRIZIANI M, MASCI G et al: Decline in te-lomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin. Cancer Res. (1997) 3:579–585.
   PubMed Web of Science ®Google Scholar
• KONDO S, KONDO Y, LI G, SILVERMAN RH, COWELL JK:Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against te-lomerase RNA. Oncogene (1998) 16:3323–3330.
   PubMed Web of Science ®Google Scholar
• •A novel antisense-directed approach against telomerase RNA showing potent in vivo antitumour activity and thus providing additional target validation.
   Google Scholar
• MATA JE, JOSHI SS, PALIN B et al: A hexameric phos-phorothioate oligonucleotide telomerase inhibitor ar-rests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharm. (1997) 144:189–197.
   PubMed Web of Science ®Google Scholar
• NORTON JC, PAITYSZEK MA, WRIGHT WE, SHAY JW, COREY DR: Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotech. (1996) 14:615–619.
   PubMed Web of Science ®Google Scholar
• HAMILTON SE, PITTS AE, KATIPALLY RR et al: Identifica-tion of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scan-ning. Biochemistry (1997) 36:11873–11880.
   PubMed Web of Science ®Google Scholar
• •By using peptide nucleic acid scanning of the hTR template region, this study identifies specific interactions important for optimal oligonucleotide recognition and binding.
   Google Scholar
• KANAZAWA Y, OHKAWA K, UEDA K et al.: Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. (1996) 225:570–576.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO K, TAKAHASHI M: Telomerase activity in hu-man leukemic cell lines is inhibited by antisense pen-tadecadeoxynucleotides targeted against c-myc mRNA. Biochem. Biophys. Res. Commun. (1997) 241:775–781.
   PubMed Web of Science ®Google Scholar
• JOSHI SS, WU AG, VERBIK DJ et al.: Oligonucleotides complementary to c-myb messenger RNA inhibit cell growth and induce apoptosis in human Burkitt lym-phoma cells. Int. J. Oncol. (1996) 8:815–820.
   PubMed Web of Science ®Google Scholar
• WANG J, XIE LY, ALLAN S, BEACH D, HANNON GJ: Myc activates telomerase. Genes Dev. (1998) 12:1769–1774.
   PubMed Web of Science ®Google Scholar
• ORR RM, MONIA BP: Antisense therapy for cancer. ID-rugs (1998) 1(2):199–205.
   PubMedGoogle Scholar
• STRAHL C, BLACKBURN EH: The effects of nucleosideanalogues on telomerase and telomeres in Tetrahy-mena. Nucleic Acids Res. (1994) 22:893–900.
   PubMed Web of Science ®Google Scholar
• PAI RB, PAI B, KUKHANOVA M et al.: Telomerase fromhuman leukemia cells: properties and its interaction with deoxynucleoside analogues. Cancer Res. (1998) 58:1909–1913.
   PubMed Web of Science ®Google Scholar
• STRAHL C, BLACKBURN EH: Effects of reverse transcrip-tase inhibitors on telomere length and telomerase ac-tivity in two immortalised human cell lines. Mol. Biol. (1996) 16:53–65.
   Web of Science ®Google Scholar
• MELANA SM, HOLLAND JF, POGO BG-T: Inhibition ofcell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'deoxythymidine. Clin. Can-cer Res. (1998) 4:693–696.
   PubMed Web of Science ®Google Scholar
• GOMEZ DE, TEJERA AM, OLIVERO OA: Irreversible telo-mere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. (1998) 246:107–110.
   PubMed Web of Science ®Google Scholar
• YEGOROV YE, CHERNOV DN, AKIMOV SS et al.: Reversetranscriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett. (1996) 389:115–118.
   PubMed Web of Science ®Google Scholar
• PERRY PJ, GOWAN SM, RESZKA AP et al.: 1,4- and 2,6-Disubstituted anthracene-9,10-dione derivatives as in-hibitors of human telomerase. J. Med. Chem. (1998) 41:3253–3260.
   PubMed Web of Science ®Google Scholar
• FLETCHER TM, SALAZAR M, CHEN S-F: Human te-lomerase inhibition by 7-deaza-2'-deoxypurine nu-cleoside triphosphates. Biochemistry (1996) 35:15611–15617.
   PubMed Web of Science ®Google Scholar
• BLACKBURN EH: Telomeres: no end in sight. Cell (1994) 77:621–623.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON JR: G-quartet structures in telomeric DNA. Ann. Rev. Biophys. Biomol. Struct. (1994) 23:703–730.
   PubMedGoogle Scholar
• RHODES D, GIRALDO R: Telomere structure and func-tion. Curr. Opin. Struct. Biol. (1995) 5:311–322.
   PubMed Web of Science ®Google Scholar
• GELLERT M, LIPSETT MN, DAVIES DR: Helix formation by guanylic acid. Proc. Natl. Acad. Sci. USA (1962) 48:2013–2018.
   PubMed Web of Science ®Google Scholar
• WANG Y, PATEL DJ: Solution structure of the human te-lomeric repeat d[AG3(T2AG3)3] G-tetraplex. Structure (1993) 1:263–282.
   PubMed Web of Science ®Google Scholar
• •A significant structure providing a well-defined starting point for the design of small molecules capable of inhibiting telomerase by preferentially interacting with human telo-meric DNA G-quadruplex structures.
   Google Scholar
• SALAZAR M, THOMPSON BD, KERWIN SM, HURLEY LH:Thermally induced DNA-RNA hybrid to G-quadruplex transitions: possible implications for telomere synthe-sis by telomerase. Biochemistry (1996) 35:16110–16115.
   PubMed Web of Science ®Google Scholar
• LIU Z, FRANTZ JD, GILBERT W, TYE B-K: Identificationand characterization of a nuclease activity specific for G4 tetra-stranded DNA. Proc. Natl. Acad. Sci. USA (1993) 90:3157–3161.
   PubMed Web of Science ®Google Scholar
• LIU Z, GILBERT W: The yeast KEM1 gene encodes a nu- clease specific for G4-tetraplex DNA: implication of in vivo functions for this novel DNA structure. Cell (1994) 77:1083–1092.
   PubMedGoogle Scholar
• SCHIERER T, HENDERSON E: A protein from Tetrahy-mena thermophila that specifically binds parallel stranded G4-DNA. Biochemistry (1994) 33:2240–2246.
   PubMed Web of Science ®Google Scholar
• LIU Z, LEE A, GILBERT W: Gene disruption of a G4-DNA-dependent nuclease in yeast leads to cellular senes-cence and telomere shortening. Proc. Natl. Acad. ScL USA (1995) 92:6002–6006.
   PubMedGoogle Scholar
• GIRALDO R, RHODES D: The yeast telomere-binding protein RAP1 binds to and promotes the formation of DNA quadruplexes in telomeric DNA. EMBO J. (1994) 13:2411–2420.
   PubMed Web of Science ®Google Scholar
• GIRALDO R, SUZUKI M, CHAPMAN L, RHODES D: Promo-tion of parallel DNA quadruplexes by a yeast telomere-binding protein: a circular dichroism study. Proc. Natl. Acad. ScL USA (1994) 91:7658–7662.
   PubMed Web of Science ®Google Scholar
• FANG G, CECH TR: The 6-subunit of Oxytricha telomere-binding protein promotes G-quartet forma-tion by telomeric DNA. Cell (1993) 74:875–885.
   PubMed Web of Science ®Google Scholar
• VAN STEENSEL B, DE LANGE T: Control of telomere length by the human telomeric protein TRF1. Nature (1997) 385:740–743.
   PubMed Web of Science ®Google Scholar
• FROELICH-AMMON SJ, DICKINSON BA, BEVILACQUA JM, SCHULTZ SC, CECH TR: Modulation of telomerase activ-ity by telomere DNA-binding proteins on Oxytricha. Genes Dev. (1998) 12:1504–1514.
   PubMed Web of Science ®Google Scholar
• ZAHLER AM, WILLIAMSON JR, CECH TR, PRESCOTT DM: Inhibition of telomerase by G-quartet DNA structures. Nature (1991) 350:718–720.
   PubMed Web of Science ®Google Scholar
• •Besides showing telomerase inhibition by G-quadruplex structures, this study also identified G-quadruplex structures as potential targets for the development of telomerase inhibitors.
   Google Scholar
• FLETCHER, TM, SUN D, SALAZAR M, HURLEY LH: Effect of DNA secondary structure on human telomerase activ-ity. Biochemistry (1998) 37:5536–5541.
   PubMed Web of Science ®Google Scholar
• PERRY PJ, GOWAN SM, RESZKA AP et al.: 1,4- and 2,6-Disubstituted anthracene-9,10-diones as inhibitors of human telomerase, a novel target for cancer chemo-therapy. Abst. Papers Amer. Chem. Soc. (1998) 215 (1):192–MEDI.
   Google Scholar
• KELLAND LR, GOWAN SM, PERRY PJ, NEIDLE S: 2,6-Disubstituted amidoanthracene-9,10-diones: Small molecule inhibitors of human telomerase. Br. J. Cancer (1998) 78(S1):18.
   Google Scholar
• KELLAND LR, GOWAN SM, PERRY PJ, NEIDLE S: Inhibi-tion of human telomerase and growth of human ovar-ian carcinoma cell lines by 2,6-disubstituted amidoanthracene-9,10-diones. Ann. OncoL (1998) 9(S1):540.
   Google Scholar
• PERRY PJ, RESZKA AP, WOOD AA et al: Human te-lomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. J. Med. Chem. (1998) 41:4873–4884.
   PubMed Web of Science ®Google Scholar
• WHEELHOUSE RT, SUN D, HAN H, HAN FX, HURLEY LH:Cationic porphyrins as telomerase inhibitors: the in-teraction of tetra-(N-methyl-4-pyridy0 porphine with quadruplex DNA. J. Amer. Chem. Soc. (1998) 120:3261–3262.
   Web of Science ®Google Scholar
• ANANTHA NV, AZAM M, SHEARDY RD: Porphyrin bind-ing to quadruplexed T4G4. Biochemistry (1998) 37:2709–2714.
   PubMed Web of Science ®Google Scholar
• ARTHANARI H, BASU S, KAWANO TL, BOLTON PH: Fluo-rescent dyes specific for quadruplex DNA. Nucleic Acids Res. (1998) 26:3724–3728.
   PubMed Web of Science ®Google Scholar
• KU W-C, CHENG A-J, WANG T-CV: Inhibition of te-lomerase activity by PKC inhibitors in human naso-pharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. (1997) 241:730–736.
   PubMed Web of Science ®Google Scholar
• YAMAKUCHI M, NAKATA M, KAWAHARA K-I, KITAJIMA I, MARUYAMA I: New quinolones, ofloxacin and levo-floxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett. (1997) 119:213–219.
   PubMed Web of Science ®Google Scholar
• BURGER AM, DOUBLE JA, NEWELL DR: Inhibition of te-lomerase activity by cisplatin in human testicular can-cer cells. Eur. J. Cancer (1997) 33:638–644.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI T, LIPPARD SJ: Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. ScL USA (1998) 95:4219–4223.
   PubMed Web of Science ®Google Scholar
• BRYAN TM, ENGLEZOU A, DALLA-POZZA L, DUNHAM MA, REDDEL RR: Evidence for an alternative mecha-nism for maintaining telomere length in human tu-mors and tumor-derived cell lines. Nature Med. (1997) 3:1271–1274.
   PubMed Web of Science ®Google Scholar